TNBC - Triple-Negative Breast Cancer Clinical Trials in Shanghai, Shanghai Municipality
4 recruitingShanghai, Shanghai Municipality, China
Showing 1–4 of 4 trials
Recruiting
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University300 enrolled1 locationNCT07551050
Recruiting
Phase 3
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting
Phase 2
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University74 enrolled1 locationNCT06387628
Recruiting
Phase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Fudan University424 enrolled2 locationsNCT05999149